The Dynamics and Prognostic Value of FDG PET-metrics in Weekly Monitoring of (chemo)radiotherapy for NSCLC
Overview
Authors
Affiliations
Purpose: To test if the relative change in FDG-PET SUV over the course of treatment was associated with disease progression and overall survival. Additionally, the prognostic values of other first-order PET-metric changes were investigated.
Methods: The study included 38 patients with stage II-III NSCLC, who underwent concurrent chemoradiotherapy. Patients received two pre-treatment FDG-PET scans and four during-treatment scans at weekly intervals. SUV was normalized to the start of treatment and analyzed using linear regression. Linear regression coefficients of other first order PET-metrics were grouped according to dissimilarity. Associations to patient outcome were analyzed using Cox hazard ratio.
Results: Twenty-eight patients satisfied the criteria for analysis. All PET-metrics demonstrated a strong linear correlation with time during treatment [median R-range: -0.87: -0.97]. No strong associations (p > 0.10) were found for the relative slope of SUV to patient outcomes. Other first-order metrics did correlate with outcome but the single imaging time-point maximizing the association of PET response with outcome varied per PET metric and outcome parameter.
Conclusion: All investigated FDG PET metrics linearly decreased during treatment. Relative change in SUV was not associated to patient outcome while several other first order PET-metrics were related to patient outcome. A single optimal imaging time-point could not be identified.
Zinn A, Kenndoff S, Holzgreve A, Kasmann L, Guggenberger J, Hering S EJNMMI Rep. 2024; 8(1):32.
PMID: 39375264 PMC: 11458843. DOI: 10.1186/s41824-024-00220-w.
Tvilum M, Knap M, Hoffmann L, Khalil A, Appelt A, Haraldsen A Clin Transl Radiat Oncol. 2024; 45():100737.
PMID: 38317680 PMC: 10839576. DOI: 10.1016/j.ctro.2024.100737.
Indovina L, Scolozzi V, Capotosti A, Sestini S, Taralli S, Cusumano D Front Med (Lausanne). 2021; 8:725387.
PMID: 34881253 PMC: 8647994. DOI: 10.3389/fmed.2021.725387.